Literature DB >> 3602349

Tissue and subcellular distribution of bismuth radiotracer in the rat: considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals.

S Zidenberg-Cherr, N J Parks, C L Keen.   

Abstract

The whole-body clearance, organ distribution, and subcellular distribution of no-carrier-added and carried-added intraperitoneally administered bismuth radiotracers (205Bi-206Bi) has been determined in Sprague-Dawley rats. Differences in clearance rate kinetics were observed for this study with the administration of neutral solutions of tracers in a carbonate buffer compared to other studies with other chemical forms. The final organ distribution was not strongly dependent on administered chemical form. We provide definitive evidence that bismuth does indeed enter subcellular organelles such as the nucleus and the mitochondria, which had 30-50% and 10-25%, respectively, of activity in kidney tissue. The kidneys were the main sink for radiotracer with uptake ranging from 20 to 50% of total body activity. The calculated energy deposition by recoil nuclei after alpha emission of potentially therapeutically useful 212Bi was found to equal or exceed the alpha energy deposition per organelle if the source is inside the cell nucleus or mitochondria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3602349

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  6 in total

1.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

Review 2.  Pharmacokinetics and toxicity of bismuth compounds.

Authors:  A Slikkerveer; F A de Wolff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

3.  Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.

Authors:  Andrey A Rosenkranz; Ganesan Vaidyanathan; Oscar R Pozzi; Vladimir G Lunin; Michael R Zalutsky; Alexander S Sobolev
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

4.  Bioavailability of bismuth from 205Bi-labelled pharmaceutical oral Bi-preparations in rats.

Authors:  B Dresow; P Nielsen; R Fischer; J Wendel; E E Gabbe; H C Heinrich
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

5.  Localization of bismuth radiotracer in rat kidney following exposure to bismuth.

Authors:  S Zidenberg-Cherr; M S Clegg; N J Parks; C L Keen
Journal:  Biol Trace Elem Res       Date:  1989-03       Impact factor: 3.738

6.  Transformation of human osteoblast cells to the tumorigenic phenotype by depleted uranium-uranyl chloride.

Authors:  A C Miller; W F Blakely; D Livengood; T Whittaker; J Xu; J W Ejnik; M M Hamilton; E Parlette; T S John; H M Gerstenberg; H Hsu
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.